Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations.
作者信息
Jung Sung Hoon, Kang Sang-Bum
机构信息
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Gut Liver. 2025 May 15;19(3):299-300. doi: 10.5009/gnl250154.
Abstract
摘要
相似文献
1
Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations.优化英夫利昔单抗在真实世界炎症性肠病中的应用：整合静脉注射和皮下注射剂型的群体药代动力学模型的见解
Gut Liver. 2025 May 15;19(3):299-300. doi: 10.5009/gnl250154.
2
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study.炎症性肠病患者静脉注射或皮下注射英夫利昔单抗的群体药代动力学模型：来自一项前瞻性队列研究的真实世界数据
Gut Liver. 2025 May 15;19(3):376-387. doi: 10.5009/gnl240503. Epub 2025 Apr 21.
3
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.重新调整英夫利昔单抗治疗方案：皮下注射英夫利昔单抗为患者提供了更便捷和更有益的治疗选择。
Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3.
4
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.炎症性肠病患者对从静脉注射英夫利昔单抗或维多珠单抗转换为皮下制剂的接受度：南希的经验。
J Clin Med. 2022 Dec 8;11(24):7296. doi: 10.3390/jcm11247296.
5
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.从强化静脉注射英夫利昔单抗转换为皮下注射英夫利昔单抗治疗炎症性肠病（DISCUS-IBD）：一项多中心随机对照试验方案。
BMJ Open. 2024 Jul 20;14(7):e081787. doi: 10.1136/bmjopen-2023-081787.
6
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.炎症性肠病中皮下注射英夫利昔单抗的治疗药物监测——在皮下生物制剂新时代理解药代动力学和暴露-反应关系
J Clin Med. 2022 Oct 19;11(20):6173. doi: 10.3390/jcm11206173.
7
Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.转换为皮下注射英夫利昔单抗维持治疗对炎症性肠病患者有效。
Dig Dis Sci. 2025 Apr;70(4):1457-1466. doi: 10.1007/s10620-025-08876-5. Epub 2025 Feb 13.
8
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.炎症性肠病患者皮下注射英夫利昔单抗维持治疗与静脉注射英夫利昔单抗维持治疗的一年临床结局：一项前瞻性队列研究。
Inflamm Bowel Dis. 2024 Apr 3;30(4):517-528. doi: 10.1093/ibd/izad094.
9
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.皮下注射英夫利昔单抗治疗风湿性疾病和炎症性肠病的观点：COVID-19 时代之前、期间和之后。
Adv Ther. 2022 Jun;39(6):2342-2364. doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 6.
10
Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: A propensity-score matched comparative analysis.英夫利昔单抗皮下注射与静脉注射在真实队列中的持续性：倾向评分匹配的比较分析。
Dig Liver Dis. 2025 Jan;57(1):325-332. doi: 10.1016/j.dld.2024.09.015. Epub 2024 Oct 8.
本文引用的文献
1
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study.炎症性肠病患者静脉注射或皮下注射英夫利昔单抗的群体药代动力学模型：来自一项前瞻性队列研究的真实世界数据
Gut Liver. 2025 May 15;19(3):376-387. doi: 10.5009/gnl240503. Epub 2025 Apr 21.
2
Precision medicine in inflammatory bowel diseases.炎症性肠病中的精准医学
Intest Res. 2024 Jan;22(1):8-14. doi: 10.5217/ir.2023.00087. Epub 2023 Nov 9.
3
Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.皮下注射英夫利昔单抗后血清浓度较高与炎症性肠病患者的深度缓解相关。
J Crohns Colitis. 2024 May 31;18(5):679-685. doi: 10.1093/ecco-jcc/jjad188.
4
Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的治疗——亚洲视角：第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):339-352. doi: 10.5217/ir.2022.00135. Epub 2023 Jul 27.
5
Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease.韩国中重度克罗恩病生物制剂临床实践指南。
Intest Res. 2023 Jan;21(1):43-60. doi: 10.5217/ir.2022.00029. Epub 2022 Oct 18.
6
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.从静脉注射到皮下注射英夫利昔单抗治疗炎症性肠病患者的效果：REMSWITCH 研究。
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. doi: 10.1016/j.cgh.2022.08.011. Epub 2022 Aug 17.
7
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.韩国中重度溃疡性结肠炎生物制剂和小分子药物临床实践指南
Intest Res. 2023 Jan;21(1):61-87. doi: 10.5217/ir.2022.00007. Epub 2022 May 31.
8
Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia.炎症性肠病的药物治疗与监测：一项在亚洲开展的多国问卷调查研究
Intest Res. 2022 Apr;20(2):213-223. doi: 10.5217/ir.2021.00031. Epub 2022 Apr 29.
9
Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.克罗恩病和溃疡性结肠炎患者皮下注射英夫利昔单抗 CT-P13 的群体药代动力学研究。
Aliment Pharmacol Ther. 2021 Nov;54(10):1309-1319. doi: 10.1111/apt.16609. Epub 2021 Sep 24.
10
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.一项真实世界人群药代动力学研究揭示了炎症性肠病中与英夫利昔单抗清除率和免疫原性相关的因素。
Inflamm Bowel Dis. 2017 Apr;23(4):650-660. doi: 10.1097/MIB.0000000000001043.
Zotero 插件